Related Experiment Video
Updated: Jul 4, 2026
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
[High PSA and total prostatectomy: specific and overall 10-year survival]
A Paul1, M Fourmarier, C Cordonnier
1Service d'urologie-transplantation, CHU Sud d'Amiens, avenue René-Laënnec-Salouël, 80054 Amiens cedex 1, France. paul.alex@hotmail.com
Summary
Radical prostatectomy for high prostate-specific antigen (PSA) levels, when carefully selected and potentially combined with radiotherapy, can offer long-term cancer control for some patients. This approach may achieve satisfactory results in select cases, demonstrating significant survival rates at 10 years.
Area of Science:
- Urology
- Oncology
- Surgical Oncology
Context:
- Radical prostatectomy is typically not recommended for patients with preoperative prostate-specific antigen (PSA) > 40 ng/ml.
- High PSA levels often indicate advanced prostate cancer, posing treatment challenges.
Purpose:
- To evaluate long-term survival outcomes in patients undergoing radical prostatectomy despite high preoperative PSA (> 40 ng/ml).
- To identify adjuvant treatments used in conjunction with surgery for this patient cohort.
Summary:
- A cohort of 32 patients with high PSA underwent radical prostatectomy with lymph node dissection.
- Mean follow-up was 117 months; 10-year specific survival was 80%, overall survival 56%, and progression-free survival 18.7%.
- Five patients received adjuvant radiotherapy, with six patients alive and without progression.
Impact:
- This study suggests that radical prostatectomy, in rigorously selected patients with high PSA and no evidence of metastasis (N0M0), possibly combined with adjuvant radiotherapy, can achieve satisfactory prostate cancer control.
- Results indicate potential long-term benefits for a subset of patients previously considered ineligible for this surgical approach.
